Cargando…
Efficacy and Safety of ATX-101 by Treatment Session: Pooled Analysis of Data From the Phase 3 REFINE Trials
BACKGROUND: ATX-101 (deoxycholic acid injection) is the only injectable drug approved for submental fat (SMF) reduction. In the phase 3 REFINE trials, adults with moderate or severe SMF who were dissatisfied with the appearance of their face/chin were eligible to receive up to 6 treatment sessions w...
Autores principales: | Dayan, Steven H, Schlessinger, Joel, Beer, Kenneth, Donofrio, Lisa M, Jones, Derek H, Humphrey, Shannon, Carruthers, Jean, Lizzul, Paul F, Gross, Todd M, Beddingfield, Frederick C, Somogyi, Christine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094350/ https://www.ncbi.nlm.nih.gov/pubmed/29401213 http://dx.doi.org/10.1093/asj/sjy008 |
Ejemplares similares
-
Submental Area Treatment with ATX-101: Relationship of Mechanism of Action, Tissue Response, and Efficacy
por: Humphrey, Shannon, et al.
Publicado: (2022) -
Best Clinical Practices with ATX-101 for Submental Fat Reduction: Patient-related Factors and Physician Considerations
por: Teller, Craig F., et al.
Publicado: (2021) -
Novel Expanded Safe Zone for Reduction of Submental Fullness with ATX-101 Injection
por: Shridharani, Sachin M., et al.
Publicado: (2019) -
Improvement in Jowl Fat following ATX-101 Treatment: Results from a Single-Site Study
por: Shridharani, Sachin M.
Publicado: (2020) -
Evaluating a Topical Adjunctive Post Submental ATX-101 (Deoxycholic Acid) Injection for Improved Recovery: A Single-Center, Double-Blind, Randomized Controlled Pilot Study
por: Shridharani, Sachin M
Publicado: (2021)